Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01953874 · ClinicalTrials.gov registry record · NA
Cardiovascular Improvements With MV ASV Therapy in Heart Failure
A NA study, sponsored by ResMed.
- Terminated
- Registry status
- NA
- Development phase
- 126
- Enrollment target
NCT01953874 is a NA study that was terminated before completion, run by ResMed. The registered enrollment target is 126 participants.
The verdict
NCT01953874, a NA study, was terminated before completion, sponsored by ResMed.
- TERMINATED
- Registry status
- NA
- Development phase
- 126 participants
- Enrollment target
Study Summary
The aim of the study is to compare the effects of MV targeted ASV in addition to optimized medical therapy versus optimized medical therapy alone at 6 months in patients with acute decompensated HF. The study will also assess changes in functional parameters, biomarkers, quality of life (QOL), and sleep.
Interventions
- DRUG Optimized Medical Treatment
- DEVICE MV ASV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2013-12 |
| Est. Completion | 2015-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01953874
The ClinicalTrials.gov registry entry for NCT01953874 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ResMed, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Optimized Medical Treatment is the first listed.
NCT01953874 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01953874 about?
NCT01953874 is a clinical study titled "Cardiovascular Improvements With MV ASV Therapy in Heart Failure". The aim of the study is to compare the effects of MV targeted ASV in addition to optimized medical therapy versus optimized medical therapy alone at 6 months in patients with acute decompensated HF. The study will also assess changes in functional parameters, biomarkers, quality of life (QOL), and s...
What is the current status of trial NCT01953874?
This trial is currently terminated. It is a NA study. The enrollment target is 126 participants. The study started on 2013-12. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01953874?
The interventions under investigation include: Optimized Medical Treatment (DRUG), MV ASV (DEVICE).
Who is sponsoring clinical trial NCT01953874?
This trial is sponsored by ResMed, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.